Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 4.21B +83.1% |
| Revenue (ttm) | 3.05B +7.6% |
| Net Income | 122.12M |
| EPS | 0.37 |
| Shares Out | 319.02M |
| PE Ratio | 35.57 |
| Forward PE | 12.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,519,852 |
| Open | 13.62 |
| Previous Close | 13.72 |
| Day's Range | 13.12 - 13.81 |
| 52-Week Range | 7.02 - 15.42 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 15.60 (+18.18%) |
| Earnings Date | May 7, 2026 |
About AMRX
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and res... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for AMRX stock is "Strong Buy." The 12-month stock price target is $15.6, which is an increase of 18.18% from the latest price.
News
Amneal Pharmaceuticals reports Q1 EPS 27c, consensus 17c
Reports Q1 revenue $722.52M, consensus $716.78M. “Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Ou...
Amneal Pharmaceuticals backs FY26 adjusted EPS view 95c-$1.05, consensus $1.00
Backs FY26 revenue view $3.05B-$3.15B, consensus $3.1B. Backs FY26 adjusted EBITDA view $740M-$770M. Backs FY26 capital expenditures view $110M.
Amneal Reports First Quarter 2026 Financial Results
‒ Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preli...
Amneal Pharmaceuticals Transcript: AGM 2026
The meeting was conducted virtually, with all director nominees elected and all proposals approved. No questions were raised by stockholders, and official voting results will be announced after verification.
Amneal Pharmaceuticals Earnings Call Transcript: Q1 2026
Announced acquisition of Kashiv BioSciences, creating a global biosimilars leader with a robust pipeline and strong Q1 results. Raised 2026 guidance, with biosimilars expected to drive significant revenue and margin growth through 2030.
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a cash-and-stock deal worth up to $1.1 billion that will expand the drugmaker's biosimilars business.
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“A...
Amneal Pharmaceuticals raises FY26 adjusted EPS view to 95c-$1.05 from 93c-$1.03
Raises FY26 revenue to $3.05B-$3.15B from $3.05B-$3.15B. Consensus is for FY26 EPS 99c and for revenue $3.1B. Reaffirms FY26 CapEx view $110M.
Amneal Pharmaceuticals to acquire Kashiv BioSciences
Amneal Pharmaceuticals (AMRX) announced that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, in a transaction with consideration that includes $375M of cash and $375M
Amneal Pharmaceuticals reports Q1 adjusted EPS 27c, consensus 17c
Reports Q1 revenue $723M, consensus $720.52M. “Amneal delivered a very strong start to 2026, reflecting the strength of our diversified business and multiple growth drivers across the portfolio. Our S...
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Grow...
Amneal announces additional interim Phase 4 ELEVATE-PD study results
Amneal Pharmaceuticals (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the 2026 American Academy of Neurology, AAN. The first 111 patients evaluat...
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” time,...
Amneal Pharmaceuticals initiated with a Buy at UBS
UBS analyst Ashwani Verma initiated coverage of Amneal Pharmaceuticals (AMRX) with a Buy rating and $19 price target The recent share selloff on the macro environment provides attractive entry point
Amneal announces U.S. launch of two respiratory metered-dose inhalation products
Amneal Pharmaceuticals (AMRX) announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol.
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. launch of albuterol sulfate inhalation aerosol an...
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5...
Amneal to Report First Quarter 2026 Results on May 1, 2026
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2026 fina...
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month
BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced donations totaling $2 million to multiple patient assistan...
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...
Amneal Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Strong 2025 results set the stage for high single-digit growth in 2026, driven by new launches in generics, injectables, and biosimilars. Specialty products CREXONT and Brekiya are outperforming, while operational shifts in AvKARE boost profitability. International and biosimilars expansion remain key priorities.
Amneal to Participate in Upcoming Investor Conference
BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside ch...
Amneal Pharmaceuticals price target raised to $17 from $15 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $17 from $15 and keeps a Buy rating on the shares. Amneal Pharmaceuticals shares pulled back slightly after
Amneal Pharmaceuticals price target raised to $17 from $15 at Truist
Truist raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $17 from $15 and keeps a Buy rating on the shares. The company reported solid Q4 results and the
Truist ups Amneal Pharmaceuticals price target, says pullback great entry point
Truist analyst Les Sulewski raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $17 from $15 and keeps a Buy rating on the shares following “solid” Q4 results. The